.jpeg)
{{ variable.name }}
Lifnua tablets (Lifnua), jointly developed by Japan's Kyorin Co., Ltd. and Merck & Co. of the United States, are the world's first selective P2X3 receptor antagonists.
Common name :Gefapixant (Gefapixant)
Trade name :LIFN UA®(リフヌア®)
Dosage form :Film-coated tablet
Main ingredient :Gefapixant Citrate, each tablet contains Gefapixant Citrate Fabisen 45mg
Excipients : Crystalline cellulose, D-mannitol, hypromellose, crospovidone, light anhydrous silicic acid, sodium stearyl fumarate, magnesium stearate, titanium oxide, triacetin, ferric oxide, Carnauba wax
Refractory chronic cough : Used to treat chronic cough that lasts for more than 1 year and cannot be relieved by adequate treatment of the cause (such as asthma, gastroesophageal reflux, etc.).
Restrictions on : It needs to be used after other clear causes (such as organic lung diseases) have been ruled out. It is a symptomatic treatment.
Specifications : 45 mg/tablet (10 tablets × 10 plates/box)
Characteristics : Round pink film-coated tablets, with a diameter of about 10.4mm, a thickness of about 5.3mm, a mass of about 463.5mg, and the identification code "777" printed on the surface.
Regular dosage of : Adults 45mg each time, taken orally twice a day.
Severe renal impairment (eGFR<30mL/min) :Adjust to 45mg once daily (those who do not require dialysis).
If you miss a dose of : Take it as soon as possible. If it is close to the next dose time, skip it. Doubling the dose is prohibited.
Diet : It can be taken before or after meals, and food has no significant effect.
Kidney impairment (eGFR30-90) : No adjustment is required, but renal function needs to be monitored regularly.
Severe renal impairment (eGFR<30) : Reduce the dose to 45 mg once daily; there is no recommended dose for dialysis patients.
Hepatic insufficiency : No adjustment required (mainly excreted by the kidneys).
Monitoring requirements : Regularly check kidney function (especially the elderly), taste function and urine (be wary of urinary tract crystals).
PTP packaging : The tablets need to be taken out to avoid esophageal damage caused by accidentally swallowing aluminum foil.
Symptomatic treatment : It is necessary to continue to investigate the cause of cough and avoid long-term blind medication.
U200c for pregnant women: Only use it when the benefits are greater than the risks (animal tests show reduced fetal weight).
U200c during lactation: Suspension of lactation (animal tests show milk migration).
Children : Safety has not been established for those under 18 years of age.
U200c for the elderly: The dose needs to be adjusted according to renal function (renal-excreted drugs).
Common (≥5%) : Abnormal taste (63.1%, such as bitter taste, metallic taste), nausea (3.7%), diarrhea (3.8%), upper abdominal pain (3.0%).
Severe but rare :
Urinary tract stones (0.8/100 person-years, related to drug crystallization).
Gesus dysgeusia (most appear within 9 days and are reversible with drug withdrawal).
(1) Those allergic to gemfapixin or sulfa drugs (including the risk of cross-allergy).
(2) Patients with active liver disease or unexplained persistent elevation of liver enzymes (caution is required when combined with statins).
Bile acid sequestrants (such as cholestyramine) : Need to be taken at intervals of 2 hours (before) or 4 hours (after).
CYP inhibitor/inducer : No significant interaction (gefapixin metabolism is not dependent on CYP).
MATE/OATP transporter substrate : The theoretical risk is low and no clinical adjustment is needed (such as omeprazole, pitavastatin).
Unopened : Store at room temperature (15-30°C), away from moisture, valid for 48 months.
After preparation : No preparation required, just take it orally.
Manufacturer : Kyorin Pharmaceutical Co., Ltd. (Japan).